Eli Lilly Omvoh Achieves 92.4% Clinical Remission Over Three Years
Eli Lilly’s Phase 3 VIVID-2 trial of Omvoh showed 92.4% clinical remission and 91.2% steroid-free remission after three years. VIVID-1 data showed nearly 50% fewer Crohn’s hospitalizations or surgeries in weeks 1–12 and almost 70% fewer in weeks 12–52, while LUCENT-3 reported one UC hospitalization and no surgeries.
1. VIVID-2 Three-Year Efficacy
Omvoh’s Phase 3 VIVID-2 extension demonstrated 92.4% clinical remission and 91.2% steroid-free remission at three years, marking the only IL-23p19 inhibitor with durable long-term efficacy in inflammatory bowel disease. Patients also experienced significant reductions in bowel urgency and sustained disease control throughout the study.
2. VIVID-1 Hospitalization and Surgery Reductions
The VIVID-1 trial in moderately to severely active Crohn’s disease showed a 16.9 vs 30.9 hospitalizations or surgeries per 100 patient-years during weeks 1–12, equating to nearly 50% fewer events versus placebo, and a 4.5 vs 14.0 rate in weeks 12–52, a 70% reduction.
3. LUCENT-3 Ulcerative Colitis Outcomes
LUCENT-3 long-term extension for ulcerative colitis reported a single UC-related hospitalization and zero surgeries over three years of Omvoh treatment, underscoring its sustained safety profile and potential to reduce invasive interventions in UC patients.
4. Competitive Positioning
As the sole IL-23p19 inhibitor showing extended durable remission, Omvoh positions Eli Lilly favorably against existing IBD therapies, supporting potential market share gains and future label expansions in Crohn’s and ulcerative colitis.